ROS-generating agent 1
Based on 1 Customer Validation
ROS-generating agent 1 is a selective ROS-generating agent. ROS-generating agent 1 inhibits TrxR activity and expression in cancer cells. ROS-generating agent 1 induces ROS-dependent apoptosis and ferroptosis in cancer cells. ROS-generating agent 1 selectively kills lung cancer cells and inhibits the growth of cancer cell xenograft tumors in nude mice. ROS-generating agent 1 can be used for the research of non-small cell lung cancer.
For research use only. We do not sell to patients.
- Purity : 99.11%
- CAS No.: 2369030-41-9
- Formula: C21H15F6NO
- Molecular Weight:411.34
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
All Caspase Isoforms
More
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
5.8 μM
Compound: 2c
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 36758308] |
| HepG2 | IC50 |
0.67 μM
Compound: 2c
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 36758308] |
| HT-1080 | IC50 |
0.93 μM
Compound: 2c
|
Cytotoxicity against human HT-1080 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human HT-1080 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 36758308] |
| MRC5 | IC50 |
14.09 μM
Compound: 2c
|
Cytotoxicity against human MRC5 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human MRC5 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 36758308] |
| NCI-H460 | IC50 |
0.44 μM
Compound: 2c
|
Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 36758308] |
In Vitro
ROS-generating agent 1 (compound 2c) (48 h) potently and selectively inhibits the viability of NCI-H460 cells (IC50 = 0.44 μM) over normal MRC-5 cells, with a selectivity index of 32.0, and also shows strong cytotoxicity against A549, HepG2, and HT-1080 cancer cells[1].
ROS-generating agent 1 (0.5-2 μM; 1-12 h) selectively induces time- and concentration-dependent ROS accumulation in NCI-H460 cells but not in normal MRC-5 cells[1].
ROS-generating agent 1 (9 h) selectively depletes intracellular GSH levels in NCI-H460 cells in a dose-dependent manner, while having no significant effect on MRC-5 cells[1].
ROS-generating agent 1 (0.5-2 μM; 6 h) dose-dependently inhibits TrxR activity in NCI-H460 cells but has negligible effect on TrxR activity in normal MRC-5 cells[1].
ROS-generating agent 1 (0.5-2 μM; 6 h) potently and dose-dependently inhibits TrxR activity in NCI-H460 cells, with 2 μM causing 59% inhibition[1].
ROS-generating agent 1 (0.5-2 μM; 6 h) dose-dependently reduces intracellular TrxR protein levels in NCI-H460 cells, with 2 μM causing 69% suppression[1].
ROS-generating agent 1 covalently binds to the Sec-498 residue of human TrxR1 with a docking affinity score of −5.494 kcal/mol, forming hydrogen bonds and a cation-π interaction with key active site residues[1].
ROS-generating agent 1 (0.5-1 μM; 48 h) kills NCI-H460 cells via induction of apoptosis and ferroptosis[1].
ROS-generating agent 1 (0.5-2 μM; 12-36 h) concentration- and time-dependently reduces mitochondrial membrane potential in NCI-H460 cells[1].
ROS-generating agent 1 (1-2 μM; 48 h) induces ROS-dependent mitochondrial-mediated apoptosis in NCI-H460 cells, as shown by altered expression of Bcl-2, Bax, caspase-9, and caspase-3[1].
ROS-generating agent 1 (0.25-0.5 μM; 40 h) selectively induces ferroptosis in a dose-dependent manner in NCI-H460 cells[1].
ROS-generating agent 1 (0.5-2 μM; 40 h) dose-dependently increases MDA levels in NCI-H460 cells[1].
ROS-generating agent 1 (0.5-2 μM; 24 h) dose-dependently reduces GPX4 protein levels in NCI-H460 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:NCI-H460 cells
-
Concentration:0.5; 1; 2 μM
-
Incubation Time:6 h
-
Result:Inhibited intracellular TrxR protein expression in a dose-dependent manner, with 2 μM suppressing 69% of TrxR expression.
-
Cell Line:NCI-H460 cells
-
Concentration:0.5; 1 μM
-
Incubation Time:48 h
-
Result:Dose-dependently reduced cell viability of NCI-H460 cells.
-
Cell Line:NCI-H460 cells
-
Concentration:1; 2 μM
-
Incubation Time:48 h
-
Result:Triggered down-regulation of anti-apoptotic Bcl-2, up-regulation of pro-apoptotic Bax, and activation of caspase-9 and caspase-3.
These changes were effectively reversed by pretreatment with NAC.
-
Cell Line:NCI-H460 cells
-
Concentration:0.5; 1; 2 μM
-
Incubation Time:24 h
-
Result:Reduced GPX4 protein expression in a concentration-dependent manner.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c nude mice (male, 5-6 weeks old) subcutaneously inoculated with NCI-H460 cells[1]
-
Dosage:5; 15 mg/kg
-
Administration:i.p.; every 2 days; 4 weeks
-
Result:Significantly and dose-dependently inhibited NCI-H460 xenograft tumor growth.
Showed no significant changes in body weight.
Exhibited no abnormal histology in liver or kidney tissues via H&E staining.
Increased tumor cell apoptosis.
Down-regulated GPX4 expression in tumor tissues compared to controls.
Chemical Information
-
CAS No. 2369030-41-9
-
Appearance Solid
-
Molecular Weight 411.34
-
Formula C21H15F6NO
-
Color Light yellow to yellow
-
SMILES
O=C1/C(CNC/C1=C\C2=CC(C(F)(F)F)=CC=C2)=C/C3=CC=CC(C(F)(F)F)=C3
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
In Vitro:
DMSO : 33.33 mg/mL (81.03 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
Patient-Derived Xenograft (PDX)
Patient-derived xenograft (PDX) models are generated by engrafting primary human tumor tissue directly into immunodeficient mice, allowing in vivo propagation of patient tumor biology without initial in vitro adaptation. These models are used to preserve key histopathological and molecular characteristics of the original tumor and enable assessment of tumor growth dynamics and therapeutic response in a living organism. The biological readout is tumor engraftment and subsequent growth in the murine host, which reflects the ability of human tumor cells to survive, vascularize, and expand in an immunocompromised microenvironment.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Splenic/Portal-Vein Liver Metastasis Xenograft
Splenic and portal-vein liver metastasis xenograft models deliver tumor cells into the portal circulation so that cells reach the liver first and form hepatic metastatic lesions; splenic injection uses the spleen as an access route to the portal system, while direct portal-vein injection introduces cells into the portal vein without requiring splenectomy. The assay detects liver colonization, intrahepatic tumor growth, tumor distribution, treatment response, survival, and liver-metastasis microenvironment changes; readouts include bioluminescence or fluorescence imaging, gross liver nodule counts, liver weight or tumor burden, histology, and survival.
-
Ferroptosis Solutions
Ferroptosis is an iron-dependent, non-apoptotic form of regulated cell death characterized by lethal lipid peroxidation and sensitivity to suppression by iron chelators or lipophilic radical-trapping antioxidants. The core pathway links cystine uptake through system Xc−, glutathione availability, GPX4-dependent detoxification of phospholipid hydroperoxides, iron-dependent oxidative reactions, and polyunsaturated-phospholipid metabolism into a cell-death program that is biochemically and morphologically distinct from apoptosis, necrosis, and autophagy. The ferroptosis pathway is experimentally linked to phenotype through chemical and genetic perturbation. Erastin induces ferroptosis by inhibiting cystine uptake through system Xc− and weakening antioxidant defenses, while GPX4 inhibition or depletion causes lipid peroxide accumulation and ferroptotic cancer-cell death. ACSL4 and oxidizable arachidonoyl- or adrenoyl-containing phosphatidylethanolamines shape ferroptosis sensitivity by con
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
-
Orthotopic Cell-Line Xenograft
Orthotopic cell-line xenograft models involve implantation of human cancer cell lines into the anatomically corresponding organ of immunodeficient mice to reproduce tumor growth within a native microenvironment, enabling more clinically relevant tumor behavior compared with subcutaneous models. These models are widely used because orthotopic placement better recapitulates tumor progression, including invasion and metastatic spread, which are often underrepresented in heterotopic implantation systems. Compared with conventional xenografts, orthotopic implantation is described as more technically complex but provides improved simulation of tumor-microenvironment interactions and metastatic behavior, making it particularly valuable for translational oncology research. Surgical orthotopic implantation approaches have been emphasized as enabling faithful reproduction of clinical cancer features, including metastasis and disease progression patterns that align with the tumor’s organ of origi
-
Intraperitoneal/Peritoneal Dissemination Xenograft
Intraperitoneal (IP) or peritoneal dissemination xenograft models are based on the introduction of human cancer cells into the peritoneal cavity of immunodeficient mice, where they attach to peritoneal surfaces, form multicellular aggregates or spheroids, and progressively generate disseminated tumor nodules that mimic advanced peritoneal metastatic disease. These models are widely used to study ovarian cancer progression, tumor-microenvironment interactions, and intraperitoneal therapeutic responses, often incorporating bioluminescence or fluorescence imaging to longitudinally monitor tumor burden in vivo. The biological principle relies on the capacity of tumor cells such as SKOV3 or related ovarian carcinoma lines to survive in suspension, aggregate within ascites-like fluid, adhere to mesothelial surfaces, and invade peritoneal organs, thereby recapitulating human peritoneal carcinomatosis patterns observed in advanced disease.
Purity & Documentation
-
Data Sheet (275 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.4311 mL | 12.1554 mL | 24.3108 mL | 60.7770 mL |
| 5 mM | 0.4862 mL | 2.4311 mL | 4.8622 mL | 12.1554 mL | |
| 10 mM | 0.2431 mL | 1.2155 mL | 2.4311 mL | 6.0777 mL | |
| 15 mM | 0.1621 mL | 0.8104 mL | 1.6207 mL | 4.0518 mL | |
| 20 mM | 0.1216 mL | 0.6078 mL | 1.2155 mL | 3.0388 mL | |
| 25 mM | 0.0972 mL | 0.4862 mL | 0.9724 mL | 2.4311 mL | |
| 30 mM | 0.0810 mL | 0.4052 mL | 0.8104 mL | 2.0259 mL | |
| 40 mM | 0.0608 mL | 0.3039 mL | 0.6078 mL | 1.5194 mL | |
| 50 mM | 0.0486 mL | 0.2431 mL | 0.4862 mL | 1.2155 mL | |
| 60 mM | 0.0405 mL | 0.2026 mL | 0.4052 mL | 1.0129 mL | |
| 80 mM | 0.0304 mL | 0.1519 mL | 0.3039 mL | 0.7597 mL |